New York Life Investment Management’s Chubb CB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-50,325
Closed -$14.2M 785
2025
Q3
$14.2M Sell
50,325
-343
-0.7% -$94.4K 0.12% 145
2025
Q2
$14.7M Buy
50,668
+845
+2% +$243K 0.14% 136
2025
Q1
$15M Sell
49,823
-458
-0.9% -$127K 0.15% 129
2024
Q4
$13.9M Buy
50,281
+291
+0.6% +$82.6K 0.14% 138
2024
Q3
$14.4M Sell
49,990
-5,748
-10% -$1.58M 0.14% 144
2024
Q2
$14.2M Buy
55,738
+399
+0.7% +$102K 0.14% 146
2024
Q1
$14.3M Sell
55,339
-2,481
-4% -$610K 0.14% 137
2023
Q4
$13.1M Sell
57,820
-13,060
-18% -$2.86M 0.13% 145
2023
Q3
$14.8M Sell
70,880
-1,726
-2% -$349K 0.16% 128
2023
Q2
$14M Sell
72,606
-6,231
-8% -$1.22M 0.15% 139
2023
Q1
$15.3M Sell
78,837
-343
-0.4% -$72.1K 0.17% 132
2022
Q4
$17.5M Sell
79,180
-806
-1% -$168K 0.2% 121
2022
Q3
$14.5M Sell
79,986
-1,393
-2% -$265K 0.18% 126
2022
Q2
$16M Buy
+81,379
New +$16.8M 0.19% 113
2015
Q4
Sell
-1,100
Closed -$114K 77
2015
Q3
$114K Buy
+1,100
New +$115K 0.01% 219

Other funds holding CB

New York Life Investment Management's CB Position: Q4 2025 in Review

New York Life Investment Management sold out of Chubb (CB) in Q4 2025, closing a stake of 50,325 shares — an estimated $14.2M sold.

New York Life Investment Management first reported a position in CB in Q3 2015 and held it in 15 quarters. The position peaked at $17.5M in Q4 2022. 2,051 funds tracked by Wall St. Rank hold CB as of Q4 2025.

  • New York Life Investment Management reported no remaining Chubb position as of Q4 2025 after selling out during the quarter.
  • New York Life Investment Management sold 50,325 Chubb shares in Q4 2025, an estimated $14.2M.
  • New York Life Investment Management first reported a position in Chubb in Q3 2015 and held it in 15 quarters.
  • New York Life Investment Management's Chubb position peaked at $17.5M in Q4 2022.
  • 2,051 funds tracked by Wall St. Rank held Chubb as of Q4 2025.

Based on New York Life Investment Management's 13F filing for Q4 2025, filed 5 Feb 2026.